
Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-7526
Dr. Bezerra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2019 - 2022
- University of WashingtonResidency, Internal Medicine, 2016 - 2019
- University of Washington School of MedicineFellowship, Bmt, 2014 - 2014
- University of Sao PauloFellowship, Hematology, 2012 - 2014
- University of Sao PauloResidency, Internal Medicine, 2010 - 2012
- Universidade Federal do Rio Grande do NorteClass of 2009, MD
Certifications & Licensure
- OH State Medical License 2022 - 2026
- MN State Medical License 2019 - 2023
- WA State Medical License 2014 - 2020
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Abstract achievement award American Society of Hematology, 2017
Publications & Presentations
PubMed
- Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma
Journal of Hematology & Oncology. 2025-03-18 - Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra
American Journal of Hematology. 2025-02-01 - 2 citationsSiltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14
Press Mentions
- New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients with Aggressive Blood CancersDecember 13th, 2023
Other Languages
- Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: